-
Something wrong with this record ?
Na(+)/K(+)-ATPase inhibition by cisplatin and consequences for cisplatin nephrotoxicity
M. Kubala, J. Geleticova, M. Huliciak, M. Zatloukalova, J. Vacek, M. Sebela
Language English Country Czech Republic
Document type Journal Article, Research Support, Non-U.S. Gov't
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
- MeSH
- Cisplatin adverse effects chemistry pharmacology MeSH
- Kidney enzymology MeSH
- Swine MeSH
- Antineoplastic Agents adverse effects chemistry pharmacology MeSH
- Sodium-Potassium-Exchanging ATPase antagonists & inhibitors chemistry MeSH
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
AIMS: Cisplatin is a widely used chemotherapeutic. However, it is associated with numerous adverse effects. The aim of our study was examination of cisplatin interaction with Na(+)/K(+)-ATPase (NKA, the sodium pump). This enzyme is of crucial importance for all animal cells and particularly for the kidney, which is frequently damaged during chemotherapy. METHODS: The entire NKA was isolated from porcine kidney. Its large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45), was heterologously expressed in E.coli (wild-type or C367S mutant). The ATPase activity was evaluated according to the inorganic phosphate production and the interaction of isolated C45 with cisplatin was studied using chronopotentiometry and mass spectrometry. RESULTS: Our experiments revealed that cisplatin can inhibit NKA. The finding that other platinum-based drugs with a low nephrotoxicity, carboplatin and oxaliplatin, did not inhibit NKA, suggested that NKA/cisplatin interaction is an important factor in cisplatin adverse effects. The inhibitory effect of cisplatin could be prevented by preincubation of the enzyme with reduced glutathione or DTT. Using chronopotentiometry and mass spectrometry, we found that cisplatin is bound to C45. However, our mutagenesis experiment did not confirm that the suggested Cys367 could be the binding site for cisplatin. CONCLUSION: Unintended interactions of drugs present serious limitations to treatment success. Although a large number of membrane pumps have been identified as potential targets of cisplatin, vis-a-vis nephrotoxicity, NKA inhibition seems to be of crucial importance. Experiments with isolated large cytoplasmic segment C45 revealed that it is the main target of cisplatin on NKA and that the reaction with cysteine residues plays an important role in cisplatin/NKA interactions. However, further experiments must be performed to identify the interacting amino acid residues more precisely.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15033220
- 003
- CZ-PrNML
- 005
- 20151030145020.0
- 007
- ta
- 008
- 151016s2014 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2014.018 $2 doi
- 035 __
- $a (PubMed)24781046
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Kubala, Martin, $u Department of Biophysics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc, Czech Republic $d 1977- $7 xx0074179
- 245 10
- $a Na(+)/K(+)-ATPase inhibition by cisplatin and consequences for cisplatin nephrotoxicity / $c M. Kubala, J. Geleticova, M. Huliciak, M. Zatloukalova, J. Vacek, M. Sebela
- 520 9_
- $a AIMS: Cisplatin is a widely used chemotherapeutic. However, it is associated with numerous adverse effects. The aim of our study was examination of cisplatin interaction with Na(+)/K(+)-ATPase (NKA, the sodium pump). This enzyme is of crucial importance for all animal cells and particularly for the kidney, which is frequently damaged during chemotherapy. METHODS: The entire NKA was isolated from porcine kidney. Its large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45), was heterologously expressed in E.coli (wild-type or C367S mutant). The ATPase activity was evaluated according to the inorganic phosphate production and the interaction of isolated C45 with cisplatin was studied using chronopotentiometry and mass spectrometry. RESULTS: Our experiments revealed that cisplatin can inhibit NKA. The finding that other platinum-based drugs with a low nephrotoxicity, carboplatin and oxaliplatin, did not inhibit NKA, suggested that NKA/cisplatin interaction is an important factor in cisplatin adverse effects. The inhibitory effect of cisplatin could be prevented by preincubation of the enzyme with reduced glutathione or DTT. Using chronopotentiometry and mass spectrometry, we found that cisplatin is bound to C45. However, our mutagenesis experiment did not confirm that the suggested Cys367 could be the binding site for cisplatin. CONCLUSION: Unintended interactions of drugs present serious limitations to treatment success. Although a large number of membrane pumps have been identified as potential targets of cisplatin, vis-a-vis nephrotoxicity, NKA inhibition seems to be of crucial importance. Experiments with isolated large cytoplasmic segment C45 revealed that it is the main target of cisplatin on NKA and that the reaction with cysteine residues plays an important role in cisplatin/NKA interactions. However, further experiments must be performed to identify the interacting amino acid residues more precisely.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a cisplatina $x škodlivé účinky $x chemie $x farmakologie $7 D002945
- 650 _2
- $a ledviny $x enzymologie $7 D007668
- 650 _2
- $a sodíko-draslíková ATPasa $x antagonisté a inhibitory $x chemie $7 D000254
- 650 _2
- $a spektrometrie hmotnostní - ionizace laserem za účasti matrice $7 D019032
- 650 _2
- $a prasata $7 D013552
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Geletičová, Jaroslava $7 _AN084818 $u Department of Biophysics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Huličiak, Miroslav $7 _AN084819 $u Department of Biophysics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Zatloukalová, Martina, $d 1986- $7 xx0170505 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc
- 700 1_
- $a Vacek, Jaroslav $7 xx0125768 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc
- 700 1_
- $a Šebela, Marek, $d 1971- $7 jo20000082920 $u Department of Protein Biochemistry and Proteomics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 158, č. 2 (2014), s. 194-200
- 856 41
- $u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20151016 $b ABA008
- 991 __
- $a 20151029083147 $b ABA008
- 999 __
- $a ok $b bmc $g 1095622 $s 916351
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 158 $c 2 $d 194-200 $e 20140429 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20151016